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Colorectal cancer and advanced adenoma detection rates among invited 
individuals in the sigmoidoscopy arm, FIT round 1, and FIT round 1-3See editorial on page 1009.
BACKGROUND & AIMS: The comparative effectiveness of
sigmoidoscopy and fecal immunochemical testing (FIT) for
colorectal cancer (CRC) screening is unknown. METHODS: In-
dividuals aged 50–74 years living in Southeast Norway were
randomly invited between 2012 and 2019 to either once-only
flexible sigmoidoscopy or FIT screening every second year.
Colonoscopy was recommended after sigmoidoscopy if any
polyp of 10mm, 3 adenomas, any advanced adenomas, orCRC was found or, subsequent to, FIT >15mg hemoglobin/
g feces. Data for this report were obtained after complete
recruitment in both groups and included 2 full FIT rounds and
part of the third round. Outcome measures were participation,
neoplasia detection, and adverse events. Age-standardized
detection rates and age-adjusted odds ratios (ORs) were
calculated. RESULTS: We included 139,291 individuals: 69,195
randomized to sigmoidoscopy and 70,096 to FIT. The partici-
pation rate was 52% for sigmoidoscopy, 58% in the first FIT
round, and 68% for 3 cumulative FIT rounds. Compared to
sigmoidoscopy, the detection rate for CRC was similar in the
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Screening with sigmoidoscopy or guaiac based fecal
occult blood tests reduce colorectal cancer mortality in
randomized controlled trials. The comparative
effectiveness of sigmoidoscopy and immunochemical
testing for fecal blood (FIT) is unknown.
NEW FINDINGS
Baseline results from this randomized effectiveness trial
show that more colorectal cancers and advanced
adenomas were detected after three cumulative rounds
of FIT compared to sigmoidoscopy screening. The risk
of perforation and significant bleeding was comparable
between the two screening modalities.
LIMITATIONS
Data not complete for third round FIT.
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ATfirst FIT round (0.25% vs 0.27%; OR, 0.92; 95% confidence
interval [CI], 0.75–1.13) but higher after 3 FIT rounds (0.49%
vs 0.27%; OR, 1.87; 95%CI, 1.54–2.27). Advanced adenoma
detection rate was lower in the first FIT round compared to
sigmoidoscopy at 1.4% vs 2.4% (OR, 0.57; 95%CI, 0.53–0.62)
but higher after 3 cumulative FIT rounds at 2.7% vs 2.4% (OR,
1.14; 95%CI, 1.05–1.23). There were 33 (0.05%) serious
adverse events in the sigmoidoscopy group compared to 47
(0.07%) in the FIT group (P¼ .13). CONCLUSIONS: Participa-
tion was higher and more CRC and advanced adenomas were
detected with repeated FIT compared to sigmoidoscopy. The
risk of perforation and bleeding was comparable. Clinicaltrials.
gov, Number: NCT01538550.
Keywords: Mass Screening; Screening Yield; Participation;
Adverse Events.
olorectal cancer (CRC) is a major health burden, with
IMPACT
Experience gained so far provides valuable information for
decision makers in implementing and improving
organized CRC screening programs.
* Authors share co-first authorship; § Authors share co-senior authorship.
Abbreviations used in this paper: ADR, adenoma detection rate; BBPS,
Boston bowel preparation scale; CI, confidence interval; CRC, colorectal
cancer; FIT, fecal immunochemical test; gFOBT, guaiac-based fecal
occult blood test; IQR, interquartile range; OR, odds ratio.
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https://doi.org/10.1053/j.gastro.2020.11.037Can estimated 1.8 million new cases worldwide in
2018.1 Screening can reduce mortality by detection of
asymptomatic early-stage cancer and prevent the disease by
the detection and removal of premalignant precursor le-
sions (adenomas and serrated polyps). In 4 randomized
trials with up to 17 years of follow-up, sigmoidoscopy
screening (endoscopic examination of the rectum and sig-
moid colon with subsequent colonoscopy if pathology is
detected) has been shown to reduce CRC mortality by 22%–
31% and incidence by 18%–26% compared to no screen-
ing.2–5 Guaiac-based fecal occult blood testing (gFOBT) has
been evaluated in 4 randomized trials with up to 30 years of
follow-up. Meta-analyses have shown a 14% reduction in
CRC mortality but no effect on CRC incidence.6
In recent years, fecal immunochemical testing (FIT) has
replaced gFOBT as the preferred fecal screening test
because of easier sampling, automatic test reading, and a
quantitative measure of fecal hemoglobin concentration to
allow adjustment of the threshold defining test positivity
and, thus, the sensitivity for adenomas and CRC.7 At lower
positivity thresholds, FIT has greater sensitivity for
advanced adenomas and CRC compared with gFOBT used in
the aforementioned randomized trials, and observational
studies have suggested that FIT may also reduce CRC inci-
dence.8 However, to our knowledge, no randomized trial
evaluating the long-term effectiveness of FIT on CRC mor-
tality or incidence has been published.
Most international guidelines recommend CRC screening
for average-risk individuals between 50 and 75 years of age,
although with differences in recommendations with respect
to the preferred screening method.9 The International Agency
for Research on Cancer recently concluded that there is
insufficient evidence to rank screening tests in terms of
effectiveness.10 Evidence from randomized population-based
clinical trials comparing different screening methods are
required to provide clear recommendations. Several trials
comparing the effect of FIT and colonoscopy screening on
long-term CRC incidence and mortality are currently under-
way.11 However, to our knowledge, no randomized trials
have compared the effectiveness of fecal occult blood testing
with sigmoidoscopy screening on CRC mortality or incidence.In this article, we report the baseline findings from a large
Norwegian randomized trial, including almost 140,000 in-
dividuals, comparing once-only sigmoidoscopy to FIT offered
every second year.Methods
Design and Participants
In 2012, all individuals 50–74 years old (born between
January 1, 1938, and December 31, 1962) living in 2 geographic
areas in Southeast Norway were identified through the popu-
lation registry and randomly assigned in a 1:1 ratio to be
invited for either once-only flexible sigmoidoscopy or FIT every
second year for a maximum of 4 rounds. Randomization was
performed by the Cancer Registry of Norway, using a computer-
based algorithm and stratified by screening center, sex, and
year of birth. No CRC screening program was available in
Norway during the conduct of the trial. The first participants
were invited in March 2012. Individuals who died, moved out
of the area, reached the upper age limit, or received a CRC
diagnosis before they were due for the first invitation were
excluded from analyses. Enrollment in the FIT group (first
round) ended in January 2017, when the predefined number of
invited individuals was reached. Enrollment in the sigmoidos-
copy group was completed in December 2018, and the last
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present study were obtained in April 2020. Accordingly, we
included all screening data from the sigmoidoscopy group and
the initial 3 FIT rounds, but because of ongoing screening,
complete data from the third FIT round were available only for
those invited for the first time before January 1, 2015 (63% of
all individuals).
The trial is run by the Cancer Registry of Norway, and 2
screening centers carried out the endoscopies. Most of the
screening sigmoidoscopies and follow-up colonoscopies were
performed by gastroenterology residents who were intensively
trained (1-to-1 supervision by an experienced endoscopist) for
3 to 6 months before entering the trial. Quality assurance
measures were closely monitored throughout the trial. Partic-
ipants were invited by mail and reminded once if there was no
response (no return of fecal sample or not attending sigmoid-
oscopy within 6 weeks). The mailed invitation included detailed
information about the randomized trial, the assigned screening
method, risks and benefits of screening, and the follow-up co-
lonoscopy in case of a positive test result. Attenders in the
sigmoidoscopy group provided written informed consent on
attendance at the screening center, whereas return of the fecal
sample was defined as consent in the FIT group. The trial was
approved by the Regional Committee for Medical Research
Ethics in Southeast Norway (2011/1272) and is registered at
clinicaltrials.gov (NCT01538550).Flexible Sigmoidoscopy
Bowel preparation for sigmoidoscopy was performed with a
240-mL sorbitol enema (Klyx, Ferring Pharmaceuticals AS)
administered on attendance. No sedation or analgesia was
provided for sigmoidoscopy. The Olympus Exera II/III systems
(Olympus H180DL/I, CF-HQ190L/I, PCF-PH190L/I, PCF-
H190DL/I) were used for sigmoidoscopies and follow-up
colonoscopies, and CO2 was the standard insufflation gas.
During most of the examinations, a magnetic imaging system
(ScopeGuide, Olympus Europa) was available. At sigmoidos-
copy, the endoscope was inserted as far as possible according
to the allocated 20-minute time slot or until a lesion 10 mm
was detected or limitations in bowel cleansing or patient
discomfort did not permit further advancement. Repeated
sigmoidoscopy was not offered in the case of an incomplete
examination. Bowel cleansing was assessed by the endoscopist
on a categorical 4-point rating scale as either poor, partially
poor, acceptable, or good. A positive sigmoidoscopy (with
subsequent referral to colonoscopy) was defined as detection of
any polyp 10 mm, 3 adenomas, an adenoma with high-grade
dysplasia or 25% villous architecture, or CRC. Polyps of <10
mm were usually removed during sigmoidoscopy.Fecal Immunochemical Test
Each FIT screening consisted of a single fecal sample. A
sampling kit and instructions were mailed together with the
invitations. Participants were not asked to apply dietary re-
strictions or to discontinue anticoagulation or antiplatelet
treatment ahead of sampling. Samples were mailed in a prepaid
envelope to the centralized laboratory at Oslo University Hos-
pital. If the fecal sample could not be mailed to the test labo-
ratory on the day of collection, participants were instructed to
keep it in the refrigerator until the next day. All samples wereanalyzed with the OC-Sensor Diana (Eiken Chemical). The
threshold defining a positive FIT was set to 15 mg hemoglobin/
g feces (corresponding to 75 ng hemoglobin/mL buffer) and
was decided after a literature search currently available at that
time. At the laboratory, the fecal samples were analyzed on the
day of arrival or stored at 4C until analysis. In case of a non-
analyzable FIT, a new test kit was sent to the participant. By
design, attenders with a negative test result and nonattenders
were reinvited every second year, up to a maximum of 4
screening rounds, or until the upper age limit was reached.Follow-Up Colonoscopies
Individuals with a positive screening result were scheduled
for a follow-up colonoscopy. Before the colonoscopy, they were
interviewed by a study nurse, either at the time of sigmoidos-
copy or by phone for those with positive FIT results. Medical
history data (including comorbidity, currently prescribed
medication use, smoking, body mass index, cancer history, and
gastrointestinal symptoms) were registered. Split-dose bowel
preparation (PicoPrep, Ferring Pharmaceuticals) was recom-
mended: 1 sachet in the afternoon before the examination and
the second dose 4 hours before the colonoscopy. The same
bowel cleansing rating scale was used as for sigmoidoscopy.
Sedation or analgesia was mainly provided on demand. In-
dividuals who had a colonoscopy were not reinvited to subse-
quent biennial rounds of FIT testing. Attenders were referred
for surveillance after colonoscopy in accordance with European
guidelines.12Data Collection and Outcome Measures
Endoscopic and histopathologic data from the sigmoidos-
copies and colonoscopies were entered into a dedicated data-
base. For all detected lesions, size, location, appearance (eg,
pedunculated, sessile, or flat), and technique and completeness
of removal were registered. CRC was defined as adenocarci-
noma of the colon or rectum. An advanced adenoma was
defined as an adenoma with either size 10 mm, villous com-
ponents of at least 25%, or high-grade dysplasia. Advanced
serrated lesions included any serrated lesions (hyperplastic
polyp, sessile serrated lesion, or traditional serrated adenoma)
with a size of 10 mm or dysplasia.13 We defined proximal
lesions as lesions localized in colonic segments proximal to and
including the splenic flexure and distal lesions as lesions
localized in colonic segments distal to the splenic flexure.
An adequate colonoscopy was defined as intubation of the
cecum with good or acceptable bowel cleansing. A sigmoidos-
copy was considered adequate if the sigmoid-descending
junction was reached or the endoscope was inserted 35 cm
without looping (verified by the external imager) and with good
or acceptable bowel cleansing.
Information on patients’ experiences, including satisfaction
and abdominal pain during sigmoidoscopy and colonoscopy,
was recorded using a questionnaire (data available only for
2012–2018).14 The participants received the questionnaire
upon leaving the colonoscopy premises and were asked to
complete the questionnaire the day after the procedure and to
return it in a prepaid envelope. Pain was categorized on a 4-
point rating scale as none, slight, moderate, or severe.
Adverse events occurring during or within 30 days after the
procedure were assessed from the health trusts’ electronic
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bleedings that lead to hospitalization (1 day), blood trans-
fusion, repeat endoscopy, radiologic intervention, or surgery.
Perforation was defined as radiologic (computer tomography)
findings consistent with intestinal perforation. Mortality within
30 days after endoscopy was obtained by linkage to the Nor-
wegian population registry. For deaths occurring within 30
days, the patients’ medical records were scrutinized by study
medical personnel to assess whether the death was possibly
related to the procedure.
CRC mortality after 10 years is the primary endpoint of the
main trial. Secondary endpoints include CRC incidence, overall
mortality, cost effectiveness, attendance rate, neoplasia detec-
tion rates, CRC stage at diagnosis, unwanted psychological15,16
and physical effects,17 and adverse events after endoscopy. In
this article, we present results for attendance rate, neoplasia
detection, CRC stage at diagnosis, and adverse events.
Statistical Analysis
For sample size calculation in the main trial, we assumed a
CRC mortality reduction of 30% in individuals invited to
sigmoidoscopy18 and 15% in individuals invited to FIT,19
compared to the general Norwegian population (no
screening). Based on a mean annual CRC mortality rate of 76/
100,000 for the first 10 years of follow-up (Norway 2010–
2012), we calculated that 70,000 individuals per arm provided
80% power to detect a 50% difference in CRC mortality
reduction between sigmoidoscopy and FIT after 10 years of
mean follow-up. Type I error was set to .05.
Detection rates for neoplasia and serrated lesions were
calculated both among invitees (intention-to-treat) and among
attenders (those who attended the screening per protocol:
attended sigmoidoscopy or returned at least 1 FIT sample).
Because enrollment by design was slower for sigmoidoscopy
compared to FIT, individuals in the sigmoidoscopy group were
older at invitation. Hence, we calculated age-standardized
detection rates in the sigmoidoscopy group, using direct stan-
dardization with age at invitation in the first round of FIT
(FIT1) as the reference (5-year age groups). At the time of
complete recruitment to the sigmoidoscopy group, 2 full FIT
rounds had been completed, and the third round was ongoing.
Accordingly, for the analysis of cumulative 3 rounds of FIT
(FIT1–3), we included only individuals invited for the first time
before January 1, 2015 (those who had been offered 3 test
rounds). We fitted logistic regression models adjusted by age
(as a continuous covariate) to compare the detection rates of
neoplasia between the screening groups and report odds ratios
(ORs) with 95% confidence intervals (CIs).
To illustrate participation rates by age, we used restricted
cubic spline univariate logistic models,20 with knots placed at
the 4 percentiles of age. When calculating the adenoma detec-
tion rate (ADR) as a performance measure for sigmoidoscopy,
we used a previously described algorithm including both ade-
nomas removed at sigmoidoscopy and adenomas detected at
sigmoidoscopy, but first removed at follow-up colonoscopy.21
Cohen k was calculated to determine the agreement between
the nonvalidated cleansing scale used in the trial and the
Boston Bowel Preparation Scale (BBPS).22 The Chi-squared test
or Fisher exact test were used to compare proportions. All tests
were 2 sided, and P < .05 was considered statistically signifi-
cant. Statistical analyses were performed by using SASsoftware, version 9.4 (SAS Institute) and Stata statistical soft-
ware, version 16.0 (StataCorp, College Station). All authors had
access to the study data and reviewed and approved the final
manuscript.Results
Of 154,743 individuals randomized, 15,452 (10%) were
excluded before the first invitation, leaving 139,291 in-
dividuals for the intention-to-treat analyses (Figure 1);
69,195 were invited to sigmoidoscopy and 70,096 to FIT.
The median age at first invitation was 63.3 years (inter-
quartile range [IQR], 58.0–69.3) in the sigmoidoscopy group
and 62.2 years (IQR, 56.6–68.1) in the FIT group (Table 1).
A total of 44,016 (63%) individuals were included in the
analyses of 3 cumulative FIT rounds. The participation rate
for sigmoidoscopy screening was 52.1%, compared to
58.4% in the first FIT round and 68.4% after 3 cumulative
FIT rounds (participation at least once) (Supplementary
Table 1). Participation was higher in the FIT group
compared to the sigmoidoscopy group for both men and
women and for all age groups (Figure 2 and Supplementary
Table 1). The participation rate was higher in women
compared to men in the FIT arm, but no difference was seen
for sigmoidoscopy screening (Supplementary Table 1).
Positivity Rates, Follow-Up Colonoscopies, and
Surveillance
In the sigmoidoscopy group, 3378 (9.4%) attenders
were referred for colonoscopy, of whom 3297 (97.6%) un-
derwent colonoscopy. Among attenders in FIT1, 3317
(8.1%) had a positive test result. Cumulative positivity rates
for FIT1–2 and FIT1–3 were 13.0% and 16.2%, respectively
(Figure 3). Colonoscopy compliance was approximately
93% in both the first and subsequent FIT rounds among
those testing FIT positive. Among the 6945 attenders who
had a colonoscopy in the FIT group, 2749 (39.6%) were
referred to polyp surveillance colonoscopy within 5 years
compared to 2158 (65.5%) of the 3297 individuals who had
a colonoscopy in the sigmoidoscopy group.
Screen-Detected Lesions
In intention-to-treat analyses, 173 patients (0.25%)
were diagnosed with CRC in FIT1 vs 202 (0.27%) in the
sigmoidoscopy group (OR, 0.92; 95% CI, 0.75–1.13). CRC
detection rates were higher in FIT1–2 (0.37%; OR, 1.38; 95%
CI, 1.15–1.66) and FIT1–3 (0.49%; OR, 1.87; 95% CI, 1.54–
2.27) compared to sigmoidoscopy (Table 2 and Figure 3).
The age-adjusted adenoma detection rate was lower in FIT1–
3 (5.8%) compared to sigmoidoscopy (9.1%; OR, 0.62; 95%
CI, 0.59–0.65), whereas the advanced adenoma detection
rate was higher in FIT1–3 (2.7%) compared to sigmoidos-
copy (2.4%; OR, 1.14; 95% CI, 1.05–1.23) (Table 2 and
Figure 3). Subgroup analyses by sex showed similar results
(Supplementary Tables 2 and 3). For all CRC stages, the
detection rate was higher after 3 cumulative FIT rounds
compared to sigmoidoscopy, and the proportion of stage I–II
vs stage III–IV CRC was similar in sigmoidoscopy, FIT1, FIT1–
154,743 individuals aged 50-74 years identified
through the population registry
77,372 individuals randomized
to once-only sigmoidoscopy
randomized 1:1
8177 excluded before invitation
1068 CRC before invitation
2179 death before invitation
2773 migrated before invitation
1835 age out of range
322 other reason*
7275 excluded before first invitation
941 CRC before invitation
1447 death before invitation
2031 migrated before invitation
197 age out of range
2328 inclusion completed
331 other reason*
77,371 individuals randomized
to FIT every second year
70,096 individuals included in
intention to treat analyses
69,195 individuals included in
intention to treat analyses
33,124
did not attend
screening
36,065
screened
22,664
did not attend
screening
47,432
screened
(at least once)
Figure 1. Flowchart. *Missing postal address (n ¼ 581), postal address abroad (n ¼ 60), withdrew consent (n ¼ 3), random-
ization error (n ¼ 2), invitation error (n ¼ 7).
March 2021 FIT Versus Sigmoidoscopy for CRC Screening 1089
CL
IN
IC
AL
AT2, and FIT1–3. However, the proportion of stage I CRC among
individuals with cancer was lower in FIT1, FIT1–2, and FIT1–3
compared to sigmoidoscopy (Table 2). The difference in
detection rates of advanced adenomas and CRC between
sigmoidoscopy and FIT1–3 was particularly pronounced for
lesions located in the proximal colon (Table 2).
In per-protocol analyses, detection rates for CRC were
higher in FIT1–3 compared to sigmoidoscopy (0.7% vs 0.5%;
OR, 1.42; 95% CI, 1.16–1.72) and lower for adenomas (8.6%
vs 17.6%; OR, 0.44; 95% CI, 0.42–0.46) and advancedTable 1.Baseline Characteristics for Included Individuals
Characteristics Sigmoidoscopy group FIT group
Included individuals, n 69,195 70,096
Sex, n (%)
Female 35,127 (50.8) 35,495 (50.6)
Male 34,068 (49.2) 34,601 (49.4)
Age at first invitation, ya
Median (IQR) 63.3 (58.0–69.3) 62.2 (56.6–68.1)
50–59, n (%) 23,960 (34.6) 28,504 (40.7)
60–69, n (%) 30,081 (43.5) 29,223 (41.7)
70, n (%) 15,154 (21.9) 12,369 (17.6)
Screening center, n (%)
Center 1 37,071 (53.6) 36,405 (51.9)
Center 2 32,124 (46.4) 33,691 (48.1)
aThe median age at randomization for the initial 154,743 in-
dividuals was 60.0 years (IQR, 54.3–66.0) in both study
groups.adenomas (3.9% vs 4.6%; OR, 0.85; 95% CI, 0.79–0.92),
respectively (Supplementary Table 4).Endoscopy Performance
Table 3 shows performance for sigmoidoscopy and
follow-up colonoscopies. Adequate sigmoidoscopy screening
was achieved for 24,800 (69.4%) attenders. The adenoma
detection rate was 16.3% at sigmoidoscopy and 58.6% at
follow-up colonoscopy in those with positive results on FIT.
The sigmoidoscopy feedback questionnaire was completed
by 24,356 (69.8%) of 34,891 individuals. Moderate or se-
vere abdominal pain was reported by 2412 (9.9%)
responders.
A total of 10,242 individuals had a colonoscopy after a
positive screening test result. The overall cecum intubation
rate was 98.1%, and the bowel cleansing was judged as
good or acceptable in 93.7%. The cecum intubation and
bowel cleansing at colonoscopy did not differ between the 2
screening groups (Supplementary Table 5). The feedback
questionnaire was completed by 7257 of 8940 individuals
(81.2%). Of those, 1756 (24.2%) reported moderate or se-
vere pain. A total of 9413 (91.9%) of the initial follow-up
colonoscopies were performed by a screening-dedicated
resident endoscopist, and the remaining were performed
by gastroenterology consultants. The screening-dedicated
endoscopists had higher ADRs at the initial colonoscopy
subsequent to a positive FIT result (57.6% vs 49.6%, P <
.001) and similar cecum intubation rates and patient-
reported pain compared to gastroenterology consultants.
In a subsample of 1291 colonoscopies, bowel cleansing
was characterized with both the 4-point scale and the BBPS;
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
50 55 60 65 70 75
Age at first invitation (years)
Participation rate (%) with 95% CI, 
males
FIT round 1-3*
FIT round 1
Sigmoidoscopy
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
50 55 60 65 70 75
Age at first invitation (years)
Participation rate (%) with 95% CI, 
females
FIT round 1-3*
FIT round 1
Sigmoidoscopy
A B
Figure 2. Participation rates by age in the sigmoidoscopy group, FIT round 1 and FIT rounds 1–3 for (A) men and (B) women,
respectively. *Participation defined as at least once across FIT rounds.
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cleansing on the 4-point scale, and 1146 (88.8%) had BBPS
of 2 in all segments (substantial agreement, k ¼ 0.730;
95% CI, 0.676–0.785; P < .001).
Adverse Events
Among 36,065 individuals attending sigmoidoscopy,
there were 3 (0.01%) perforations (2 of these were most
likely caused by the enema tip and 1 related to polypectomy,
all conservatively treated) and 3 (0.01%) significant bleed-
ings. Two individuals died within 30 days of a diagnostic
sigmoidoscopy. None of these deaths were considered
related to the screening procedure.
Among the 10,242 participants who had at least 1 co-
lonoscopy, 7 (0.07%) perforations and 67 (0.65%) signifi-
cant bleedings occurred, all related to polypectomy. One of
the perforations was surgically treated (without stoma), and
6 were conservatively treated with antibiotics. Two in-
dividuals died within 30 days after colonoscopy. One of
these deaths was probably related to the procedure. The
person was older than 70 years, had a preexisting coronary
disease, and died of an acute myocardial infarction within
24 hours after the colonoscopy.
In total, there were 33 (0.05%) significant bleedings or
perforations (sigmoidoscopy and follow-up colonoscopy)
among individuals invited in the sigmoidoscopy group
compared to 47 (0.07%) significant bleedings or perfora-
tions among invitees in the FIT group (P ¼ .13).
Discussion
In this large randomized trial, we show that both
repeated FIT and once-only sigmoidoscopy are feasible
screening methods. However, participation was already
higher in the first round of FIT compared to sigmoidoscopyand increased in the second and third screening rounds.
After 3 FIT screening rounds, more CRCs and advanced
adenomas were detected than by sigmoidoscopy. Impor-
tantly, the adverse event rates did not differ between the 2
screening methods.
In contrast to screening sigmoidoscopy, biennial
screening for fecal occult blood with gFOBT has not been
shown to reduce CRC incidence in randomized trials, and no
results for FIT have been published.6 No randomized trial
comparing the effectiveness of repeated FIT with sigmoid-
oscopy screening on CRC mortality and incidence currently
exists. Previous studies comparing detection rates of FIT vs
sigmoidoscopy screening included only 1 FIT round, were
nonrandomized, had small sample sizes, or had poor
participation rates in the sigmoidoscopy arm (28.1%–
32.4%).23–26 One of the trials, combining results from 3
Dutch screening cohorts, found higher detection rates for
advanced neoplasia and CRC with 4 rounds of FIT compared
to sigmoidoscopy.24 However, the nonrandomized design
and low participation at sigmoidoscopy makes interpreta-
tion difficult. Our participation rates were high both for
sigmoidoscopy (52%) and for FIT (58% for the first round,
68% for at least 1 round) compared to the published liter-
ature and the minimum target recommended by European
Union guidelines (45%).27
The higher number of advanced adenomas among
invited individuals in the FIT group compared to sigmoid-
oscopy in our trial may indicate a potential effect not only
on CRC mortality but also CRC incidence reduction. How-
ever, it needs to be considered that more nonadvanced
adenomas were removed by sigmoidoscopy screening than
in the FIT group. A higher detection rate of advanced ade-
nomas with cumulative FIT rounds may be caused by
transformation of nonadvanced adenomas over time. This
may imply that once-only sigmoidoscopy detects most
0.27 0.25
0.37
0.49
0.0
0.1
0.2
0.3
0.4
0.5
0.6
Detection rates CRC (%), 
both sexes 
2.4
1.4
2.1
2.7
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Detection rates AA (%), 
both sexes
0.33 0.32
0.46
0.58
0.0
0.1
0.2
0.3
0.4
0.5
0.6
Detection rates CRC (%), 
males
0.21
0.18
0.29
0.40
0.0
0.1
0.2
0.3
0.4
0.5
0.6
Detection rates CRC (%), 
females
3.0
1.7
2.6
3.3
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Detection rates AA (%), 
males
1.8
1.0
1.6
2.0
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Detection rates AA (%), 
females
9.4
8.1
13.0
16.2
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
18.0
20.0
Positivity rate (%), 
both sex
7.0 6.7
10.9
13.7
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
18.0
20.0
Positivity rate (%), females
11.8
9.7
15.4
19.0
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
18.0
20.0
Positivity rate (%), malesA B C
FED
H IG
Figure 3. (A–I) Positivity rates and age-standardized detection rates CRC and advanced adenoma (AA) among invited in-
dividuals in the sigmoidoscopy group, FIT round 1 (FIT1), FIT rounds 1–2 (FIT1–2) and FIT round 1–3 (FIT1–3) for both sexes,
male and female.
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Table 2.Findings Among Invited Individuals (Intention-to-Treat Analyses) in the Sigmoidoscopy Group, FIT Round 1, FIT Rounds 1–2, and FIT Rounds 1–3
Finding
Sigmoidoscopy (n ¼ 69,195) FIT round 1 (n ¼ 70,096) FIT rounds 1–2 (n ¼ 70,096) FIT rounds 1–3 (n¼ 44,016)
n %a n % OR (95% CI)b n % OR (95% CI)b n %a OR (95% CI)b
Colorectal cancer 202 0.27 173 0.25 0.92 (0.75–1.13) 260 0.37 1.38 (1.15–1.66) 210 0.49 1.87 (1.54–2.27)
Proximalc 21 0.03 41 0.06 2.08 (1.23–3.52) 77 0.11 3.92 (2.42–6.36) 63 0.15 5.47 (3.33–8.99)
Distalc 181 0.24 134 0.19 0.79 (0.64–0.99) 187 0.27 1.11 (0.90–1.36) 152 0.36 1.51 (1.21–1.87)
Stage I 130 0.17 87 0.12 0.72 (0.55–0.95) 133 0.19 1.10 (0.86–1.40) 101 0.24 1.40 (1.08–1.82)
Stage II 22 0.03 33 0.05 1.61 (0.94–2.77) 54 0.08 2.66 (1.62–4.37) 55 0.13 4.53 (2.76–7.46)
Stage III 40 0.06 40 0.06 1.06 (0.68–1.64) 56 0.08 1.47 (0.98–2.21) 45 0.11 1.96 (1.27–3.01)
Stage IV 10 0.01 13 0.02 1.37 (0.60–3.13) 17 0.02 1.82 (0.83–3.97) 9 0.02 1.67 (0.68–4.14)
Other cancerd,e 26 0.04 7 0.01 0.27 (0.12–0.61) 13 0.02 0.50 (0.25–0.97) 10 0.02 0.60 (0.29–1.26)
Adenomad 6396 9.06 1793 2.56 0.27 (0.25–0.28) 3163 4.53 0.48 (0.46–0.50) 2485 5.79 0.62 (0.59–0.65)
Proximalc 1425 1.98 1040 1.49 0.76 (0.70–0.82) 1863 2.67 1.38 (1.28–1.48) 1474 3.45 1.81 (1.68–1.95)
Distalc 6126 8.68 1405 2.01 0.22 (0.20–0.23) 2447 3.50 0.38 (0.37–0.40) 1895 4.42 0.49 (0.46–0.51)
Advanced adenomad 1699 2.38 950 1.36 0.57 (0.53–0.62) 1478 2.12 0.89 (0.83–0.96) 1132 2.65 1.14 (1.05–1.23)
Proximalc 271 0.37 275 0.39 1.08 (0.91–1.28) 428 0.61 1.68 (1.44–1.96) 331 0.77 2.19 (1.86–2.57)
Distalc 1577 2.21 787 1.13 0.51 (0.47–0.55) 1214 1.74 0.79 (0.73–0.85) 922 2.16 0.99 (0.91–1.07)
3 nonadvanced
adenomasd
424 0.58 217 0.31 0.53 (0.45–0.63) 434 0.62 1.07 (0.94–1.23) 358 0.85 1.47 (1.27–1.69)
Advanced serrated
lesionsd
632 0.89 209 0.30 0.34 (0.29–0.39) 404 0.58 0.65 (0.58–0.74) 330 0.76 0.88 (0.77–1.00)
Proximalc 296 0.42 138 0.20 0.48 (0.39–0.59) 279 0.40 0.97 (0.82–1.14) 234 0.54 1.33 (1.12–1.59)
Distalc 409 0.58 83 0.12 0.21 (0.16–0.26) 146 0.21 0.36 (0.30–0.44) 109 0.25 0.44 (0.36–0.55)
aAge-standardized rates.
bCompared to sigmoidoscopy and adjusted by age.
cThe sum may exceed the total number because of the possibility of findings in both the proximal and distal colon.
dIndividuals with CRC detected at screening are excluded from analyses when calculating other cancers, adenomas, and serrated lesions.
eOther cancer includes screening-detected neuroendocrine tumors, squamous cell carcinomas, and lymphomas.
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Table 3.Performance Measures and Severe Adverse Events
at Sigmoidoscopy and Colonoscopy After a Positive
Screening Test Result
Indicator Sigmoidoscopy
Follow-up
colonoscopy
Participating individuals, n 36,065 10,242
Intubation depth, cm,
median (IQR)
50 (40–56) N/A
Cecum intubated, n (%) N/A 10,043 (98.1)
Withdrawal time 6 minutes,
n (%)a
N/A 2015/2077 (97.0)
On-demand sedation or
analgesia, n (%)
N/A 3206 (31.3)
Bowel cleansing quality, n (%)b
Good 20,950 (58.7) 7476 (74.1)
Acceptable 6580 (18.4) 1978 (19.6)
Partly poor 7089 (19.9) 551 (5.5)
Poor 1091 (3.1) 84 (0.8)
Adequate examination, n (%)b 24,800 (69.4) 9293 (92.1)
Adenoma detection rate, n (%) 5894 (16.3) 4073 (58.6)c
Major adverse events, n (%)
Perforation 3 (0.01) 7 (0.07)
Significant bleedingd 3 (0.01) 67 (0.65)
Death 0 (0.00) 1 (0.01)
Patient-reported pain, n (%)e
None 14,975 (61.5) 2883 (39.7)
Slight 6969 (28.6) 2618 (36.1)
Moderate 1642 (6.7) 1047 (14.4)
Severe 770 (3.2) 709 (9.8)
Patient satisfaction, n (%)e
Satisfied 22,949 (98.4) 6703 (97.9)
Not satisfied 374 (1.6) 141 (2.1)
N/A ¼ not applicable.
aProportion of complete diagnostic colonoscopies (no poly-
pectomy or biopsy) with time from cecum to end of procedure
of 6 minutes.
bBowel cleansing quality missing for 355 sigmoidoscopy
participants and 153 colonoscopy participants.
cIn the FIT group (n ¼ 6945).
dSignificant bleeding was defined as requiring hospital
admission, repeat endoscopy, blood transfusion, radiologic
intervention, or surgery.
ePercentages among responding individuals (in years 2012–
2018).
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screening over time will detect more adenomas at an
advanced stage. Thus, FIT screening may not be more
effective than sigmoidoscopy screening to reduce CRC inci-
dence. Also, more CRCs might be detected in subsequent FIT
rounds because adenomas may transform to invasive le-
sions over time. These lesions might have been detected as
noninvasive lesions if sigmoidoscopy screening was per-
formed. Our trial aims at disentangling these mostimportant features as it continues toward its primary
endpoint of the comparison of CRC mortality and incidence
after 10 years of follow-up. Presently, our data do not
support any conclusion with respect to the superiority of
any screening method. However, we believe that our results
may be informative for researchers who work with
screening modeling. The number of CRCs and advanced
adenomas detected per screened individual in the present
study is within the range reported from previous
sigmoidoscopy21,28–30 and FIT screening trials with com-
parable cutoffs (10–20 mg hemoglobin/g feces).23,31–33
Our result suggests that FIT screening might result in
greater protection against proximal cancer development
and death in the long term compared to sigmoidoscopy
screening. This may be explained by FIT detecting bleeding
in the entire colon, whereas sigmoidoscopy examines only
the distal colon and rectum. We also show a difference in
stage distribution between sigmoidoscopy and FIT in our
trial, with a higher proportion of stage I CRC in the
sigmoidoscopy group compared to 3 cumulative FIT rounds.
However, the absolute number of stage I CRC detected was
similar after 2 rounds of FIT and will be higher after 3
complete FIT rounds compared to sigmoidoscopy.
In our analyses of screened individuals (per-protocol
analyses), CRC detection rates were higher after 3 rounds of
FIT screening compared to sigmoidoscopy. The advanced
adenoma detection rate increased with increasing FIT
rounds but was still slightly lower after 3 FIT rounds
compared to sigmoidoscopy. However, per-protocol ana-
lyses are difficult to interpret because of the inherent risk of
selection bias.
The effect of a CRC screening program relies on high-
quality colonoscopies with few adverse events. Most endo-
scopists in our trial had little endoscopy experience when
they were recruited but received intensive training and
were closely monitored and given feedback on key quality
indicators throughout the trial. The colonoscopy perfor-
mance was excellent, with a cecum intubation rate of 98%
and a bowel cleansing quality above the requirements for
screening colonoscopies.34 Also, the adenoma detection rate
at follow-up colonoscopy in our trial (58.6%) is within the
range of other FIT screening programs (37%–65%)35–37
and higher than the benchmarks for colonoscopy after a
positive FIT result (45% for men and 35% for women)
suggested by the US Multi-Society Task Force on Colorectal
Cancer.38
Limited colonoscopy capacity is a bottleneck for endo-
scopic CRC screening. We show that recruitment and
training of high-quality endoscopists is feasible within a
rather short timeframe. However, this result requires suffi-
cient resources (eg, experienced endoscopist trainers)
available for teaching. The number of referrals for follow-up
colonoscopy and for colonoscopy surveillance was higher
after 3 rounds of FIT compared to sigmoidoscopy. Thus, the
higher CRC and advanced adenoma detection is accompa-
nied by an increased demand for colonoscopy. On the other
hand, sigmoidoscopy is an invasive procedure associated
with some discomfort, work absenteeism, and risk of
adverse events, whereas FIT testing per se is not.6,39
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events occur. The rates of significant bleedings (0.65%) and
perforations (0.07%) among individuals having a colonos-
copy in the present trial is in line with those reported from
the English gFOBT screening program (0.65% bleeding and
0.06% perforation rate).40 Importantly, we show that sig-
nificant bleedings and perforations were equally frequent
among those invited for sigmoidoscopy compared to those
invited to FIT so far. However, with increasing rounds of FIT
screening, the number of adverse events in the FIT group
may exceed the number among those invited for sigmoid-
oscopy screening.
Almost one quarter of individuals undergoing colonos-
copy reported moderate or severe pain. This is probably a
consequence of providing sedation on demand during co-
lonoscopy and must be weighed against possible harms and
disadvantages of more or deeper sedation. The reputation of
the screening procedure should also be considered, as fear
of pain has been shown to be a barrier to screening
participation.41 However, despite the relatively high rate of
self-reported pain, the majority of screening attenders re-
ported that they were satisfied with the examination.
The main strength of this study is the population design
with no consent before inclusion—mimicking an organized
screening program. Second, we included multiple FIT
rounds in the analysis, which allows for a fair comparison
on diagnostic yield compared to once-only sigmoidoscopy.
Other strengths include the large sample size; the relatively
high participation rates at screening; and the availability of
information on performance measures, adverse events, and
patient experience in this trial.
The study also has limitations. First, the design of the
study with all individuals being randomized at one point in
time (in 2012) and a slower invitation rate for sigmoidos-
copy led to a mean age difference of 1 year at the time of
first invitation between the 2 study groups. To avoid a po-
tential bias related to the increased prevalence of CRC and
advanced adenomas by age,42 we age-adjusted detection
rates as described in the Methods section. Another limita-
tion is incomplete data from the third FIT round (63%).
Because the data set is large, however, we do not expect
substantial changes in detection rates when the third round
is complete. Third, we did not have any information of
nonstudy colonoscopies performed before or during the
course of the trial. Currently, there is no CRC screening
program in Norway, and opportunistic screening is the
indication for less than 5% of colonoscopies, according to
the Norwegian colonoscopy quality registry (Gastronet).43
According to a European survey from 2014, approximately
30% of the population aged 50–74 years in Norway have
had a colonoscopy within the last 10 years.44 Individuals
with a previous colonoscopy were presumably equally
distributed between the 2 arms at the time of randomiza-
tion, but we cannot rule out that a previous colonoscopy
history has had a different impact on screening uptake or
findings at screening in the 2 arms. Also, our results may not
be generalizable to populations with a different prevalence
of colonoscopy history. In Norway, a national screening
program will commence in 2021 with biennial FIT, startingat age 55 years. Although participants in the current trial
will not be eligible for the national program, its introduction
may influence the population’s awareness of CRC and co-
lonoscopy referral practice among physicians. It cannot be
ruled out that implementation of a nationwide screening
program may affect the long-term outcome in the 2 trial
arms differently. The final results will not be obtained until
10 years of follow-up. Even with this long timeframe, results
from large randomized trials like ours will offer important
information for policy makers with regard to the upcoming
screening program in Norway and in other countries where
screening programs are already in place or imminent.
Fourth, there is a risk that individuals in the same
household were randomized to different arms of the trial.
This might have influenced their behavior in ways relating to
the exposure (screening method) or outcome (CRC). Fifth,
because of increased awareness of serrated lesions over the
last 2 decades, there is a possibility that serrated lesions may
have been inconsistently classified during the trial. However,
no significant increase in serrated lesion detection rates was
seen over time (data not shown). Sixth, the high number of
inadequate sigmoidoscopies may affect the detection rate in
the sigmoidoscopy arm. However, adequate bowel prepara-
tion is not obtained as easily with enemas as with oral for-
mulations used for full colonoscopy cleansing, and the
adenoma detection at sigmoidoscopy in our trial was higher
(16.3%) than that reported from both the UK flexible
sigmoidoscopy trial (12.1% distal adenomas)29 and the Ital-
ian randomized controlled trial of once-only sigmoidoscopy
(SCORE-trial) trial (10.8% distal adenomas)28 but in line with
the Norwegian Colorectal Cancer Prevention (NORCCAP) trial
(16.6% any neoplasm).45 Of note, the age groups included
were younger in NORCCAP (50–64 years) and the UK and
Italian trials (55–64 years) compared to the present trial (50–
74 years), and criteria for referral to colonoscopy differed
among the trials (any polyp sized 10 mm or biopsy-verified
neoplasia in the NORCCAP trial, adenomas meeting high-risk
criteria or any polyp 10 mm in the UK trial, and high-risk
adenoma or any polyp 5 mm in the Italian SCORE trial),
making a direct comparison of ADR difficult.
It is worth mentioning that a threshold of 15 mg/g for
FIT positivity in the current trial is relatively low, and our
results may not be applicable to programs choosing other
cutoff values. Finally, our results on participation and
effects might not be generalizable to populations with
other distributions of socioeconomic background and
education levels, but these data were not available in the
current trial.Conclusion
Baseline results from this randomized, comparative
effectiveness trial showed higher detection rates for
advanced adenomas and CRC with 3 cumulative FIT rounds
compared to once-only sigmoidoscopy. Both methods are
feasible in Norway, with acceptable participation rates and
comparable complication rates. Long-term follow-up data
on CRC mortality and incidence are not expected until 10
years of follow-up.
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Supplementary Table 1.Screening Participation, Positivity Rates, and Colonoscopy Attendance in the Sigmoidoscopy Group,
FIT Round 1, FIT Rounds 1–2, and FIT Rounds 1–3 by Sex and by Age at First Invitation
Participant subgroup
Sigmoidoscopy
(n ¼ 69,195)
FIT round 1
(n ¼ 70,096)
FIT rounds 1–2
(n ¼ 70,096)
FIT rounds 1–3
(n ¼ 44,016 )
Participating individuals, n (%)a 36,065 (52.1) 40,966 (58.4)b 45,687 (65.2)b 30,110 (68.4)b
Sex
Female 18,246 (51.9) 21,791 (61.4)b 24,085 (67.9)b 15,854 (70.9)b
Male 17,8198 (52.3) 19,175 (55.4)b 21,602 (62.4)b 14,256 (65.8)b
Age group, y
50–59 11,971 (50.0) 15,404 (54.0)b 17,696 (62.1)b 12,850 (66.1)b
60–69 16,496 (54.8) 18,125 (62.0)b 20,000 (68.4)b 12,899 (71.6)b
70 7598 (50.1) 7437 (60.1)b 7991 (64.6)b 4361 (66.4)b
Positive screening test result, n (%)c 3378 (9.4) 3317 (8.1)d 5958 (13.0)b 4883 (16.2)b
Sex
Female 1275 (7.0) 1461 (6.7) 2627 (10.9)b 2173 (13.7)b
Male 2103 (11.8) 1856 (9.7)d 3331 (15.4)b 2710 (19.0)b
Age group, y
50–59 812 (6.8) 947 (6.1)d 1832 (10.4)b 1724 (13.4)b
60–69 1581 (9.6) 1517 (8.4)d 2787 (13.9)b 2326 (18.0)b
70 985 (13.0) 853 (11.5)d 1339 (16.8)b 833 (19.1)b
Attended colonoscopy, n (%)e 3297 (97.6) 3107 (93.7)d 5555 (93.2)d 4525 (92.7)d
Sex
Female 1234 (96.8) 1361 (93.2)d 2441 (92.9)d 2010 (92.5)d
Male 2063 (98.1) 1746 (94.1)d 3114 (93.5)d 2515 (92.8)d
Age group, y
50–59 794 (97.8) 901 (95.2)d 1728 (94.3)d 1610 (93.4)d
60–69 1544 (97.7) 1423 (93.8)d 2604 (93.4)d 2154 (92.6)d
70 959 (97.4) 783 (91.8)d 1223 (91.3)d 761 (91.4)d
aParticipation is defined as at least once across FIT rounds.
bP < .05 compared to sigmoidoscopy, in favor of FIT.
cPercentages among individuals attending screening.
dP < .05 compared to sigmoidoscopy, in favor of sigmoidoscopy.
ePercentages among individuals with a positive screening test result.
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Supplementary Table 2.Findings Among Invited Women in the Sigmoidoscopy Group, FIT Rounds 1, 1–2, and 1–3
Finding
Sigmoidoscopy
(n ¼ 35,127) FIT round 1 (n ¼ 35,495) FIT rounds 1–2 (n ¼ 35,495) FIT rounds 1–3 (n ¼ 22,359)
n %a n % OR (95% CI)b n % OR (95% CI)b n %a OR (95% CI)b
Colorectal cancer 79 0.21 64 0.18 0.86 (0.62–1.19) 102 0.29 1.36 (1.02–1.83) 89 0.40 1.96 (1.45–2.67)
Proximalc 12 0.03 23 0.06 2.03 (1.01–4.09) 41 0.12 3.64 (1.91–6.94) 37 0.17 5.59 (2.91–10.77)
Distalc 67 0.18 42 0.12 0.66 (0.45–0.98) 63 0.18 0.99 (0.70–1.40)) 55 0.25 1.42 (0.99–2.03)
Stage I 49 0.13 33 0.09 0.71 (0.46–1.11) 48 0.14 1.03 (0.69–1.54) 37 0.17 1.31 (0.85–2.01)
Stage II 10 0.03 14 0.04 1.49 (0.66–3.36) 25 0.07 2.68 (1.29–5.59) 31 0.14 5.38 (2.63–11.02)
Stage III 14 0.04 11 0.03 0.82 (0.37–1.81) 22 0.06 1.63 (0.83–3.18) 17 0.08 2.08 (1.02 –4.25)
Stage IV 6 0.02 6 0.02 1.06 (0.34–3.30) 7 0.02 1.25 (0.42–3.73) 4 0.02 1.27 (0.36–4.55)
Other cancerd,e 9 0.03 4 0.01 0.45 (0.14–1.46) 8 0.02 0.90 (0.35–2.34) 5 0.02 0.85 (0.28–2.56)
Adenomad 2545 7.15 695 1.96 0.26 (0.24–0.29) 1237 3.50 0.47 (0.44–0.51) 971 4.41 0.61 (0.56–0.65)
Proximalc 421 1.16 346 0.98 0.85 (0.74–0.99) 657 1.86 1.64 (1.45–1.86) 526 2.41 2.17 (1.90–2.47)
Distalc 2461 6.92 533 1.50 0.21 (0.19–0.23) 940 2.66 0.37 (0.34–0.40) 729 3.31 0.46 (0.43–0.51)
Advanced adenomad 635 1.76 359 1.01 0.58 (0.51–0.66) 568 1.61 0.92 (0.82–1.03) 446 2.04 1.18 (1.05–1.34)
Proximalc 68 0.19 85 0.24 1.32 (0.96–1.81) 144 0.41 2.24 (1.67–2.99) 118 0.54 3.03 (2.24–4.10)
Distalc 607 1.68 299 0.84 0.50 (0.44–0.58) 471 1.33 0.79 (0.70–0.90) 367 1.68 1.01 (0.89–1.16)
3 nonadvanced
adenomasd
113 0.31 63 0.18 0.58 (0.43–0.80) 138 0.39 1.28 (1.00–1.65) 111 0.51 1.68 (1.29–2.19)
Advanced serrated
lesiond
302 0.84 103 0.29 0.35 (0.28–0.43) 202 0.57 0.68 (0.57–0.82) 166 0.75 0.91 (0.75–1.10)
Proximalc 152 0.42 69 0.19 0.46 (0.35–0.62) 147 0.42 0.99 (0.79–1.25) 131 0.59 1.44 (1.14–1.83)
Distalc 190 0.53 40 0.11 0.21 (0.15–0.30) 65 0.18 0.35 (0.26–0.46) 45 0.20 0.39 (0.28– 0.54)
aAge-standardized detection rates.
bCompared to sigmoidoscopy and adjusted by age.
cThe sum may exceed the total number because of the possibility of findings in both the proximal and distal colon.
dIndividuals with CRC detected at screening are excluded from analyses when calculating other cancers, adenomas, and serrated lesions.
eOther cancer includes screening detected neuroendocrine tumors, squamous cell carcinomas, and lymphomas.
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Supplementary Table 3.Findings Among Invited Men in the Sigmoidoscopy Group, FIT Rounds 1, 1–2, and 1–3
Finding
Sigmoidoscopy
(n ¼ 34,068) FIT round 1 (n ¼ 34,601) FIT rounds 1–2 (n ¼ 34,601) FIT rounds 1–3 (n ¼ 21,657)
n %a n % OR (95% CI)b n % OR (95% CI)b n %a OR (95% CI)b
Colorectal cancer 123 0.33 109 0.32 0.96 (0.74–1.24) 158 0.46 1.39 (1.10–1.76) 121 0.58 1.81 (1.40–2.33)
Proximalc 9 0.02 18 0.05 2.14 (0.96–4.77) 36 0.10 4.29 (2.07–8.93) 26 0.12 5.30 (2.47–11.36)
Distalc 114 0.31 92 0.27 0.87 (0.66–1.15) 124 0.36 1.18 (0.91–1.52) 97 0.47 1.57 (1.19–2.06)
Stage I 81 0.21 54 0.16 0.73 (0.51–1.02) 85 0.25 1.14 (0.84–1.55) 64 0.31 1.46 (1.05–2.03)
Stage II 12 0.03 19 0.05 1.72 (0.83–3.54) 29 0.08 2.64 (1.34–5.17) 24 0.12 3.81 (1.90–7.66)
Stage III 26 0.07 29 0.08 1.19 (0.70–2.02) 34 0.10 1.38 (0.83–2.31) 28 0.14 1.89 (1.10–3.24)
Stage IV 4 0.01 7 0.02 1.83 (0.53–6.27) 10 0.03 2.66 (0.83–8.50) 5 0.02 2.26 (0.60–8.51)
Other cancerd,e 17 0.05 3 0.01 0.17 (0.05–0.59) 5 0.01 0.29 (0.11–0.78) 5 0.02 0.47 (0.17–1.28)
Adenomad 3851 11.02 1098 3.18 0.27 (0.25–0.28) 1926 5.59 0.48 (0.45–0.51) 1514 7.23 0.63 (0.59–0.67)
Proximalc 1004 2.81 694 2.01 0.72 (0.65–0.79) 1206 3.50 1.27 (1.16–1.38) 948 4.53 1.67 (1.53–1.83)
Distalc 3665 10.48 872 2.53 0.22 (0.21–0.24) 1507 4.38 0.39 (0.37–0.42) 1166 5.58 0.50 (0.47–0.54)
Advanced adenomad 1064 3.01 591 1.71 0.57 (0.51–0.63) 910 2.64 0.88 (0.81–0.96) 686 3.29 1.11 (1.01–1.23)
Proximalc 203 0.56 190 0.55 1.00 (0.82–1.22) 284 0.82 1.49 (1.25–1.79) 213 1.02 1.91 (1.57–2.32)
Distalc 970 2.75 488 1.41 0.51 (0.46–0.57) 743 2.16 0.78 (0.71–0.86) 555 2.66 0.97 (0.88–1.08)
3 nonadvanced
adenomasd
311 0.86 154 0.45 0.51 (0.42–0.63) 296 0.86 0.99 (0.85–1.17) 247 1.20 1.40 (1.18–1.65)
Advanced serrated
lesiond
330 0.93 106 0.31 0.33 (0.26–0.41) 202 0.59 0.63 (0.53–0.75) 164 0.78 0.84 (0.70–1.02)
Proximalc 144 0.41 69 0.20 0.49 (0.37–0.66) 132 0.38 0.94 (0.74–1.19) 103 0.49 1.22 (0.94–1.57)
Distalc 219 0.61 43 0.12 0.20 (0.14–0.28) 81 0.24 0.38 (0.29–0.49) 64 0.30 0.49 (0.37–0.65)
aAge-standardized detection rates.
bCompared to sigmoidoscopy and adjusted by age.
cThe sum may exceed the total number because of the possibility of findings in both the proximal and distal colon.
dIndividuals with CRC detected at screening are excluded from analyses when calculating other cancers, adenomas, and serrated lesions.
eOther cancer includes screening detected neuroendocrine tumors, squamous cell carcinomas, and lymphomas.
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Supplementary Table 4.Findings Among Individuals Actually Screened (Per-Protocol Analyses) in the Sigmoidoscopy Group
and FIT Rounds 1, 1–2, and 1–3
Sigmoidoscopy
(n ¼ 36,065) FIT round 1 (n ¼ 40,966) FIT rounds 1–2 (n ¼ 45,687) FIT rounds 1–3 (n ¼ 30,110)
Detection
rate, %a
Detection
rate, % OR (95% CI)b
Detection
rate, %a OR (95% CI)b
Detection
rate, %a OR (95% CI)b
Colorectal cancer 0.53 0.42 0.80 (0.65–0.98) 0.58 1.10 (0.91–1.31) 0.73 1.42 (1.16–1.72)
Proximalc 0.05 0.10 1.81 (1.07–3.06) 0.17 3.11 (1.92–5.03) 0.22 4.15 (2.52–6.81)
Distalc 0.48 0.33 0.69 (0.55–0.86) 0.42 0.88 (0.71–1.08) 0.53 1.14 (0.92–1.42)
Stage I 0.34 0.21 0.62 (0.48–0.82) 0.30 0.87 (0.68–1.11) 0.35 1.06 (0.82–1.38)
Stage II 0.06 0.08 1.40 (0.82–2.40) 0.12 2.10 (1.28–3.45) 0.19 3.44 (2.09–5.65)
Stage III 0.11 0.10 0.92 (0.59–1.43) 0.12 1.17 (0.78–1.75) 0.16 1.48 (0.97–2.28)
Stage IV 0.03 0.03 1.19 (0.52–2.72) 0.04 1.44 (0.66–3.15) 0.03 1.27 (0.51–3.14)
Other cancerd,e 0.07 0.02 0.24 (0.10–0.54) 0.03 0.40 (0.20–0.77) 0.03 0.46 (0.22–0.96)
Adenomad 17.58 4.40 0.22 (0.20–0.23) 7.01 0.35 (0.34–0.37) 8.57 0.44 (0.42–0.46)
Proximalc 3.86 2.55 0.66 (0.61–0.71) 4.14 1.09 (1.01–1.16) 5.12 1.37 (1.27–1.48)
Distalc 16.84 3.44 0.18 (0.17–0.19) 5.42 0.28 (0.27–0.30) 6.54 0.34 (0.33–0.36)
Advanced adenomad 4.63 2.33 0.49 (0.46–0.54) 3.28 0.70 (0.65–0.75) 3.93 0.85 (0.79–0.92)
Proximalc 0.73 0.67 0.94 (0.79–1.11) 0.95 1.33 (1.14–1.55) 1.16 1.66 (1.41–1.95)
Distalc 4.30 1.93 0.44 (0.40–0.48) 2.69 0.62 (0.57–0.67) 3.20 0.74 (0.68–0.81)
3 nonadvanced
adenomasd
1.14 0.53 0.46 (0.39–0.55) 0.97 0.85 (0.74–0.97) 1.26 1.11 (0.96–1.28)
Advanced serrated
lesiond
1.73 0.51 0.29 (0.25–0.34) 0.89 0.52 (0.46–0.59) 1.13 0.66 (0.58–0.76)
Proximalc 0.81 0.34 0.42 (0.34–0.51) 0.62 0.77 (0.65–0.90) 0.80 1.01 (0.85–1.20)
Distalc 1.12 0.20 0.18 (0.14–0.23) 0.32 0.29 (0.24–0.35) 0.37 0.34 (0.27–0.42)
aAge-standardized detection rates.
bCompared to sigmoidoscopy and adjusted by age.
cThe sum may exceed the total number because of the possibility of findings in both the proximal and distal colon.
dIndividuals with CRC detected at screening are excluded from analyses when calculating other cancers, adenomas, and
serrated lesions.
eOther cancer includes screening detected neuroendocrine tumors, squamous cell carcinomas, and lymphomas.
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Supplementary Table 5.Performance Measures and Severe
Adverse Events at Colonoscopy
After a Positive Screening Test
Result by Screening Method
Indicator
Follow-up
colonoscopy
after
sigmoidoscopy
Follow-up
colonoscopy
after FIT P
Individuals, n 3297 6945
Cecum intubated, n (%) 3245 (98.4) 6798 (97.9) .065
Withdrawal time 6
minutes, n (%)a
302/317 (95.3) 1713/1760
(97.3)
.047
On-demand sedation or
analgesia, n (%)
944 (28.6) 2262 (32.6) <.001
Bowel cleansing quality,
n (%)b
Good 2456 (75.3) 5020 (73.5) .087
Acceptable 610 (18.7) 1368 (20.0)
Partly poor 177 (5.4) 374 (5.5)
Poor 19 (0.6) 65 (1,0)
Adequate examination,
n (%)b
3025 (92.7) 6268 (91.8) .108
Adenoma detection rate,
n (%)
N/A 4073 (58.6) N/A
Major adverse events,
n (%)
Perforation 4 (0.12) 3 (0.04) .222
Significant bleedingc 23 (0.70) 44 (0.63) .707
Death 0 (0.00) 1 (0.01) 1.000
Patient reported pain,
n (%)d
None 823 (40.3) 1620 (38.7) .001
Slight 762 (37.3) 1472 (35.2)
Moderate 297 (14.5) 626 (15.0)
Severe 160 (7.8) 466 (11.1)
Patient satisfaction, n (%)d
Satisfied 1988 (97.9) 4096 (97.8) .886
Not satisfied 43 (2.1) 91 (2.2)
N/A ¼ Not applicable.
aThe proportion of complete diagnostic colonoscopies (no
polypectomy or biopsy) with a time from cecum to end of
procedure of 6 minutes.
bBowel cleansing quality was missing for 118 individuals at
follow-up colonoscopy after FIT and 35 individuals after
sigmoidoscopy.
cSignificant bleeding is defined as requiring hospital admis-
sion, repeat endoscopy, blood transfusion, radiologic inter-
vention, or surgery.
dPercentages among responding individuals (in years 2012
and 2014–2018).
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